Ampreloxetine Data in Neurogenic Orthostatic Hypotension to

/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data in neurogenic...

Related Keywords

San Diego , California , United States , Dublin , Ireland , American , Theravance Biopharma , Andrew Hindman , Stroy Freeman , Company Phase , American Autonomic Society , Clinical Program Demonstrates Ampreloxetine , Uc San Diego Health Movement Disorder Center , Beth Israel Deaconess Medical Center , International Symposium , Theravance Biopharma Inc , Company Form , Securities Exchange , Prnewswire Theravance Biopharma Inc , Viatris Company , Program Demonstrates Ampreloxetine , Treating Symptoms , Improving Activities , Daily Living , Neurogenic Orthostatic Hypotension , Autonomic Nervous System , Peripheral Nerve Disorders , Blood Pressure , Pure Autonomic Failure , Orthostatic Hypotension Symptom Assessment , Orthostatic Hypotension Daily Activities Scale , Orthostatic Hypotension Questionnaire , Orthostatic Hypotension Symptom Assessment Scale , Patient Global Impression , Multiple System Atrophy , Symptomatic Neurogenic Orthostatic Hypotension , Private Securities Litigation Reform Act , Securities Exchange Act ,